Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema

Terminated Mashhad University of Medical Sciences

Single-blindTreatment

Summary

Purpose: to evaluate the effect of intravitreal injection of tissue plasminogen activator(tPA) in treatment of refractory diabetic macular edema(DME).

Timeline

Start: 2009-05
Primary completion: 2010-01
Completion: 2010-03

Outcome

Outcome not reported

Stopped: “occurrence of retinal hemorrhage , increase in macular edema of some patients in TPA group”

Publications

Background Murakami T, Takagi H, Ohashi H, Kita M, Nishiwaki H, Miyamoto K, Watanabe D, Sakamoto A, Yamaike N, Yoshimura N. Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. Retina. 2007 Oct;27(8):1031-7. doi: 10.1097/IAE.0b013e318074bc39.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alteplase	Protein / enzyme biologic	25 ug	Intravitreal
Background	Bevacizumab	Monoclonal antibody	1.25 mg	—